Retrieved from Haber, R., Zarzour, F., Ghezzawi, M., et al
Para continuar, ingresa atu cuenta trace-id: e4cf6ca2-e3c2-4750-87f3-1cc79c3b3c4a Usamos cookies para mejorar tu experiencia en Mercado Libre
2007;137(3 Suppl 2):830S-837S
In the monotherapy era, when every patient with obesity got handed roughly the same molecule, the genetic question was interesting but not load-bearing
The panel includes a lipid panel, a comprehensive metabolic panel (CMP), and a hemoglobin A1c (HbA1c) panel: Lipid panel : establishes baseline cholesterol and triglycerides to track cardiovascular-related changes during GLP-1 treatment [4] Comprehensive metabolic panel (CMP) : evaluates 14 biomarkers related to organ function, electrolytes, and metabolic health to get a baseline for monitoring the drugs effectiveness and potential side effects like dehydration [5] Hemoglobin A1c (HbA1c) : measures average blood sugar over 23 months to assess long-term glucose control and guide diabetes-related treatment decisions [6] Together, these tests provide baseline metabolic and cardiovascular information that helps Levity providers safely prescribe and monitor GLP1 medications for weight management
Importantly, genetic predisposition does not predict exact medication response, but it does offer a more granular understanding of your individual risk landscape
